Kura Oncology, Inc. Stock News

Kura Oncology, Inc. ( KURA ) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia November 13, 2025 12:30 PM EST Company Participants Greg Mann Troy Wilson - Chairman, CEO & President Mollie Leoni - Chief Medical Officer Brian Powl - Chief Commercial Officer Conference Call Participants Eunice Wang Daniel Bronder Jonathan Chang - Leerink Partners LLC...

– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – – FDA grants full approval of KOMZIFTI ahead of PDUFA target action date – – Approval is based on the KOMET-001 trial, in which KOMZIFTI demonstrated deep responses, a potentially b...

The U.S. Food and Drug Administration has approved Kura Oncology's drug to treat a rare form of blood cancer that has returned or resisted initial therapy, the regulator said on Thursday.

SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conference:

SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisti...

Kura Oncology, Inc. ( KURA ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Greg Mann Thomas Doyle - Senior Vice President of Finance & Accounting Troy Wilson - Chairman, CEO & President Mollie Leoni - Chief Medical Officer Brian Powl - Chief Commercial Officer Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Jason Zemansky - BofA...

– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 –

– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials – – Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials –